The Pfizer / BioNTech vaccine has been shown to be effective against the so-called ‘British strain’ of COVID-19, the Financial Times has advanced. The coronavirus mutation VOC-202012/01 or B.1.17 was identified in England last October from a sample that was collected in September and has since spread significantly over other variants, also by other European countries. Pharmaceuticals were conducting studies to see if the serum was also effective against her. The Pfizer / BioNTech vaccine is the one that is being administered mainly in Spain: we already have 1,107,600 doses, of which 957,314 have been inoculated in patients. We also have 35,700 of Moderna.
It is still under investigation, but preliminary studies indicate that this mutation is more contagious because it has a change in the spike of the virus (the ‘spikes’ that sprout from the body) that allow it to better bind to proteins in human cells. In Spain there are around a hundred confirmed cases of the British strain, which have been sequenced, and there are many others under investigation at the National Center for Microbiology, according to the Minister of Health.RELATED
Viruses mutate frequently, and the coronavirus in particular undergoes an average of 1-2 mutations per month (flu viruses, by comparison, undergo 4-8 mutations per month). Several experts had already advanced that vaccines take this particularity into account. The researcher in genomic sequencing of the Fisabio Fernando González-Candelas foundation explained to this newspaper a few weeks ago that they are prepared for a virus that mutates “continuously”, and that the main problem with these new variants is their effects on the collapse of the health system .
The Pfizer / BioNTech vaccine was the first vaccine approved by the European Commission last December. It began to be used in Spain on December 27 and 600 million doses are planned for all of Europe. Remittances of 350,000 doses arrive weekly in Spain, which just this week had a reduction of 56%, initially on time. The company wants to increase its production for the year and had to make manufacturing adjustments to do so, which caused it, they alleged.
On January 6, Moderna (160 million for the entire continent) was given the green light, and by the end of January the University of Oxford / AstraZeneca (300) is also expected to have it. The European Union has pre-contracts with four others that have not yet passed all clinical trials: Sanofi-GSK (300 million doses for all of Europe), Johnson & Johnson (200), CureVac (225) and Novavax (without the contract closed, for 200). All have the possibility of an additional purchase.